Multicentre Trials
The following table provides a list of open multicentre trials using the UK PET Core Lab to provide site accreditation and quality control procedures for the PET component of the study. For more details on an individual study please click on the trial name to view more details. Whilst we try to keep information about the trials up-to-date, this information should only be used as a guide and the trial co-ordinator for the study should be contacted directly for further information on the trial.
| Short Name | Full Title |
|---|---|
| ANIMATE | A phase II study of nivolumab monotherapy in patients with relapsed/refractory Hodgkin lymphoma, fit for autologous stem cell transplant, who fail to reach complete metabolic remission after first or second line salvage therapy |
| AVENuE | Avelumab in the frontline treatment of advanced classical Hodgkin lymphoma - a window study |
| [18F]FPIA PET/CT imaging in patients with solid tumours | An investigation of short-chain fatty acid uptake in solid tumours as assessed by [18F]fluoropivalate positron emission tomography and its relationship with tumour proliferation |
| PANORAMA | Analysis of PSMA expressioN in prOstate cancer and its relationship with the presence of nodAl MetastAses |
| PETReA | PETReA: Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma |
| PRIMUS-002 | An umbrella phase II study examining two neo-adjuvant regimens (FOLFOX-A and AG) in resectable and borderline resectable Pancreatic Ductal AdenoCarcinoma (PDAC), focusing on biomarker and liquid biopsy development |
| RADAR | A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previously untreated stage IA/IIA Hodgkin lymphoma |
| REMIT | RadiothErapy priMIng for CAR-T |
| REMoDL-A | A Randomised Phase II Evaluation of Molecular Guided Therapy for Diffuse Large B-Cell Lymphoma with Acalabrutinib |
| SCOPE 2 | A randomised Phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemo-radiation with an embedded Phase II trial for patients with a poor early response using positron emission tomography (PET) |
The following table provides a list of the multicentre trials that used the UK PET Core Lab to provide site accreditation and quality control procedures for the PET component of the study and are now in follow-up or completed.
| Short Name | Full Title |
|---|---|
| ABLE | Afatinib Before Lung surgEry: a study investigating the effect of giving a course of a targeted tablet treatment called afatinib to patients with potentially curable non-small cell lung cancer during the short interval between their diagnosis and the removal of their cancer by surgery |
| AZD3965 | A Phase I Trial of AZD3965 in Patients With Advanced Cancer |
| BACCHUS | A phase II Multicentre Open-label Randomised Study of Neoadjuvant Chemotherapy and Bevacizumab in Patients with MRI defined High-Risk Cancer of the Rectum |
| BREVITY | A phase II study of brentuximab vedotin using a response adapted design in patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity |
| CARDAMON | Carfilzomib/Cyclophosphamide/Dexamethasone with maintenance carfilzomib in untreated transplant-eligible patients with symptomatic MM to evaluate the benefit of upfront ASCT |
| CHEMO-T | Cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) versus gemcitabine, cisplatin and methyl prednisolone (GEM-P) in the first line treatment of T-cell Lymphoma, a multicentre randomised phase II study |
| EURONET_PHL_C2 | Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents |
| FALCON | A phase 3, open-label study to assess the clinical utility of Fluciclovine (F-18) PET/CT in patients with prostate cancer with biochemical recurrence after radical treatment |
| FGFR Study | Proof-of-concept study of AZD4547 in patients with FGFR1 or FGFR2 amplified tumours |
| IELSG-37 | A randomized, open label, multicentre, two-arm phase III comparative study assessing the role of mediastinal radiotherapy after rituximab containing chemotherapy regimens to patients with newly diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL) |
| LEGEND | A randomised phase II study comparing LEnalidomide plus rituximab, GEmcitabine and methylprednisolone (LR-GEM) to rituximab, gemcitabine, methylprednisolone and cisplatiN (RG-EMP) in second-line treatment of Diffuse Large B-cell lymphoma (DLBCL) |
| MAPPING | Diagnostic accuracy of MRI, diffusion-weighted MRI, FDGPET/CT and Fluoro-ethyl-choline PET/CT in the detection of lymph node metastases in surgically staged endometrial and cervical carcinoma |
| PAIReD | Phase II study of reduced intensity allogeneic transplantation for refractory Hodgkin lymphoma |
| PET after 2 cycles in NHL (R-CHOP 14vs21 PET sub-study) | Blinded evaluation of prognostic value of FDG-PET after 2 cycles of chemotherapy in Diffuse Large B-cell Non-Hodgkin's Lymphoma |
| PET-PANC | The impact of combined modality positron emission tomography with computerised tomography scanning (PET/CT) in the diagnosis and management of pancreatic cancer |
| POETIC: FLT-PET sub-study | Trial of Perioperative Endocrine Therapy - Individualising Care: FLT-PET sub-study |
| RAPID | A Randomised Phase III Trial to Determine the Role of FDG-PET Imaging in Clinical Stages IA/IIA Hodgkins Disease |
| RATHL | A randomised Phase III trial to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced Hodgkin Lymphoma |
| REASURE | A phase 2 open-label study of biomarkers to assess response in patients with metastatic castration resistant prostate cancer treated with radium-223 |
| ReBeL | ReBeL study: a randomized phase I/II trial of lenalidomide and rituximab with or without bendamustine in patients >= 18 years with relapsed follicular lymphoma. A HOVON/GLSG/NCRI study |
| SPUtNIk | Solitary Pulmonary Unidentified Nodule Investigation: Accuracy and Cost-Effectiveness of Dynamic Contrast Enhanced Computed Tomography in the Characterisation of Solitary Pulmonary Nodules |
| STO3 PET Sub-study | A Randomised Phase II/III trial of Perioperative Chemotherapy with or without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and (in selected centres) A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinomas. FDG-PET Sub-study |
| TITAN | Randomised controlled open-label trial of TPF induction chemotherapy in the surgical management of locally advanced head and neck cancer |
| TORCH | A phase II study to determine the safety and efficacy of the dual mTORC inhibitor AZD2014 and to investigate additional toxicities in combination with rituximab in relapsed refractory DLBCL |